Biolase Inc
BIOLASE, Inc., together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosme… Read more
Biolase Inc (BIOLQ) - Net Assets
Latest net assets as of September 2024: $-5.23 Million USD
Based on the latest financial reports, Biolase Inc (BIOLQ) has net assets worth $-5.23 Million USD as of September 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($27.24 Million) and total liabilities ($32.47 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-5.23 Million |
| % of Total Assets | -19.19% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 115.55 |
Biolase Inc - Net Assets Trend (2020–2023)
This chart illustrates how Biolase Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Biolase Inc (2020–2023)
The table below shows the annual net assets of Biolase Inc from 2020 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $-247.00K | -105.05% |
| 2022-12-31 | $4.89 Million | -80.61% |
| 2021-12-31 | $25.21 Million | +151.38% |
| 2020-12-31 | $10.03 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Biolase Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 6542400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $316.55 Million | % |
| Total Equity | $-247.00K | 100.00% |
Biolase Inc Competitors by Market Cap
The table below lists competitors of Biolase Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
AFRICA PRUDENTIAL PLC
XNSA:AFRIPRUD
|
$88.98 |
|
Green For Energy Inc
PINK:GRGG
|
$89.19 |
|
Muller & Phipps PLC
CM:MULLN0000
|
$89.30 |
|
Everest Global PLC
LSE:EVST
|
$89.45 |
|
CN ZHENGTONG
BE:ZA0
|
$88.63 |
|
Chenab Ltd Pref
KAR:CLCPS
|
$88.22 |
|
LiveChain Inc
PINK:LICH
|
$88.13 |
|
Jervois Global Limited
BE:IHS
|
$88.08 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Biolase Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 4,889,000 to -247,000, a change of -5,136,000 (-105.1%).
- Net loss of 20,632,000 reduced equity.
- New share issuances of 15,043,000 increased equity.
- Other factors increased equity by 453,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-20.63 Million | -8353.04% |
| Share Issuances | $15.04 Million | +6090.28% |
| Other Changes | $453.00K | +183.4% |
| Total Change | $- | -105.05% |
Book Value vs Market Value Analysis
This analysis compares Biolase Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $256.70 | $0.01 | x |
| 2021-12-31 | $410.09 | $0.01 | x |
| 2022-12-31 | $63.32 | $0.01 | x |
| 2023-12-31 | $-0.07 | $0.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Biolase Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -41.97%
- • Asset Turnover: 1.40x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-204.40%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -167.82% | -73.88% | 0.56x | 4.09x | $-17.83 Million |
| 2021 | -64.10% | -41.23% | 0.71x | 2.19x | $-18.68 Million |
| 2022 | -585.68% | -59.09% | 1.27x | 7.81x | $-29.12 Million |
| 2023 | 0.00% | -41.97% | 1.40x | 0.00x | $-20.61 Million |
Industry Comparison
This section compares Biolase Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Biolase Inc (BIOLQ) | $-5.23 Million | -167.82% | N/A | $88.72 |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |